New Developments in Inhaled Antibiotics for the Treatment of Pseudomonas aeruginosa

Title: New Developments in Inhaled Antibiotics for the Treatment of Pseudomonas aeruginosa

Volume: 18 Issue: 5

Author(s): Thomas Hofmann

Affiliation:

Keywords: Inhaled antibiotics, Pseudomonas aeruginosa, cystic fibrosis, aerosol, lung delivery, pneumonia, aerosolized application, tobramycin, drug delivery, nebulizer

Abstract: The field of inhaled antibiotics that target Pseudomonas aeruginosa infections has made substantial contributions to the health, disease management, and life expectancies of individuals with cystic fibrosis (CF) over the last three decades [1-3]. This paper reviews some of the recent clinical developments in the field of inhaled antibiotics for CF and briefly describes formulations and ongoing developments for US and/or European regulatory approvals. Lung delivery technologies, in regards to inhaled antibiotics for CF, are also reviewed

Cite this article as:

Hofmann Thomas, New Developments in Inhaled Antibiotics for the Treatment of Pseudomonas aeruginosa, Current Pharmaceutical Design 2012; 18 (5) . https://dx.doi.org/10.2174/138161212799315975